NEUROCRINE BIOSCIENCES, INC.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 216
- Registration Number
- NCT05182476
- Locations
- 🇪🇸
Neurocrine Clinical Site, Madrid, Spain
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 93
- Registration Number
- NCT05165394
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 101
- Registration Number
- NCT05159908
- Locations
- 🇪🇸
Neurocrine Clinical Site, Valencia, Spain
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 400
- Registration Number
- NCT05110157
- Locations
- 🇷🇸
Neurocrine Clinical Site, Vršac, Serbia
🇺🇸Neurocrine Clinical Sites, Glen Oaks, New York, United States
🇷🇸Neurocrine Clinical Site 1, Kragujevac, Serbia
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 31
- Registration Number
- NCT04880616
- Locations
- 🇳🇱
Neurocrine Clinical Site, Leiden, CL, Netherlands
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 52
- Registration Number
- NCT04873869
- Locations
- 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸Children's National Hospital, Washington, District of Columbia, United States
🇺🇸University of Rochester, Rochester, New York, United States
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 103
- Registration Number
- NCT04806451
- Locations
- 🇬🇧
Neurocrine Clinical Site, London, United Kingdom
🇺🇸Neurocrine Clinical site, Saint Louis, Missouri, United States
Opicapone Treatment Initiation Open-Label Study
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 239
- Registration Number
- NCT04787965
- Locations
- 🇺🇸
Neurocrine clinical site, Crab Orchard, West Virginia, United States
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT04625101
- Locations
- 🇬🇧
Neurocrine Clinical Site, London, United Kingdom
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 182
- Registration Number
- NCT04490915
- Locations
- 🇬🇧
Neurocrine Clinical Site, Salford, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath